

SK chemicals  
2025 4Q Earnings Release



We care for the future.  
**Healthcare, Earthcare**



## Disclaimer

The financial information in this document are consolidated earnings results based on K-IFRS. (Korea International Financial Reporting Standards)

The performance data for Q4 2025 included in this material has been prepared for the convenience of investors and has not yet been reviewed by an external auditor. Therefore, some of the content may change during the accounting review process.

Additionally, please note that the future outlook included in this material is based on the current business environment and the company's management strategy and may change due to future changes in the business environment and strategy adjustments.

1


# Earnings Release

---

Company Highlight  
Performance Summary



# 4Q25 Highlight



# Performance Summary

## Consolidated

**Revenue 622bn KRW** (+20.6% YoY, +1.9% QoQ)

Top-line expansion driven by increased sales from consolidated subsidiaries and the Pharma business

**Operating Profit  $\Delta 39$ bn KRW** (Turn to a Loss YoY, QoQ)

Turned to Loss as losses from consolidated subsidiaries widened

## Separate


**Revenue 338bn KRW** ( $\Delta 2.5\%$  YoY,  $\Delta 9.1\%$  QoQ)

Despite increase in Pharma business, Sales decreased due to low performance in Copolyester business


**Operating Profit 3.8bn KRW** ( $\Delta 88.2\%$  YoY,  $\Delta 87.4\%$  QoQ)

Profit decreased due to weaker profitability in Copolyester and higher one-off expenses


### Revenue




### Operating Profit and Margin



### Revenue




### Operating Profit and Margin



# 2 Performance

---



# Performance by Business Unit (1)

## Green Chemicals – Copolyester & Monomer

### 4Q25 Performance

Revenue **201bn KRW** ( $\Delta 3.5\% \text{ YoY}$ ,  $\Delta 3.7\% \text{ QoQ}$ )

**Delayed recovery in global demand,  
Customer de-stocking led to lower revenue**

Operating Profit **19bn KRW** ( $\Delta 37.3\% \text{ YoY}$ ,  $\Delta 45.6\% \text{ QoQ}$ )


**Lower sales volume and the impact of  
scheduled maintenance weighed on profit**

### 1Q26 Outlook

Strengthen positioning  
in high-value markets  
through portfolio diversification


#### Revenue

(Unit: billion KRW)




#### Operating Profit and Margin

(Unit: billion KRW)



\* Including performance of America/Europe copolyester sales subsidiaries

### Sales Volume Proportion by Region



■ China ■ EU/America ■ Korea ■ Japan etc

\* Data above only refers to Copolyester sales

### Applications



Cosmetics



Household goods  
& Home appliances



Resin

Interior sheet &  
Packaging films etc

# Performance by Business Unit (2)

## Life Science - Pharma

### 4Q25 Performance

Revenue **126bn KRW** (+18.3% YoY, △9.0% QoQ)

Continuing strong sales  
of key products and distribution

Operating Profit **5bn KRW** (△91.7% YoY, △94.8% QoQ)


Increases in R&D, marketing, and  
one-off costs compressed profit

### 1Q26 Outlook

Establish growth drivers based on  
sales growth of key products and  
expansion of in-licensed products


#### Revenue

(Unit: billion KRW)



#### Operating Profit and Margin

(Unit: billion KRW)



### Revenue Proportion



### Main Products



#### Joins

Natural product based  
anti-arthritis treatment



#### Ginexin

blood circulation  
disorder treatment &  
Cognitive enhancer



#### Rivastigmine patch

Anti-dementia  
treatment patch



# Performance by Business Unit (3)

## Life Science - SK bioscience

### 4Q25 Performance

**Revenue** **184bn KRW** (+17.4% YoY, +22.2% QoQ)  
**Growth of Flu & Varicella Vaccines** and higher IDT Sales to key customers and productivity improvements


**Operating Profit** **△52bn KRW** (Loss Continued YoY, QoQ)  
One-off costs such as IDT retirement benefits were recognized

### 1Q26 Outlook

Growth in SKYVAX exports and Sanofi Vaccine distribution, Continue to improve IDT operation efficiency


#### Revenue

(Unit: billion KRW)



#### Operating Profit

(Unit: billion KRW)



## Overview

### SKYVAX

- SKYCellflu: Despite price declines from the domestic shift to trivalent, sales grew on the back of expanded global exports
- SKYVaricella: Stable supply to PAHO and export expansion to Latin America and Southeast Asia
- SKYZoster: Expanded coverage through continued growth in local gov't procurement, export expansion in Asia

### Vaccine distribution

- Sanofi 'Beyfortus'(RSV): Preventive antibody injection expansion, newly launched the meningococcal vaccine 'MenQuadfi'

### IDT Biologika

- Sales growth centered on key customers; improved operational efficiency

### RSV in-licensing agreement — Gates MRI

- Pursuing entry as the third global player; secured a pipeline targeting developed markets (U.S. Phase 1a completed)

### Accelerating next-generation Ebola vaccine development with CEPI


# Business Update

---



# Recycle Growth Strategy

Establishing a leading position in the global recycling market by completing the end-to-end value chain



**"Achieving global competitiveness through the internalization of core assets at every stage of the value chain and offering tailored, optimized solutions to customers."**

# Recycle Achievements

Expanding collaboration areas with key automotive partners; gradual progress becoming visible

## Establishment of a JV to build Feedstock Innovation Center



Process low-quality feedstocks such as waste blankets and fines<sup>1)</sup> to produce high-quality recycled PET raw materials at competitive prices

- Securing stability of Feedstock Supply
- Reducing feedstock costs by securing new types of waste
- Leveraging local partner capabilities and networks



△ Establishment of a joint venture with China's PET recycling company Kelinle

### Timeline



1) Fines refer to micro-particles generated during the PET bottle shredding process, which occur as by-products when processing MR-PET

# Recycle Achievements

In response to circularity regulations such as SUPD<sup>1)</sup> and ELV<sup>2)</sup>, expanding collaboration with key customers and results gradually becoming visible

## Automotive Commercialization



Tirecord for EV cars

2Q 2024



Supplied to the global No.1 tire cord company and applied to Hankook Tire's EV tires

Tirecord for EV cars



Carmat for major car makers

3Q 2025



"Introduce new premium brand "

Collaborated with the world's leading car mat company and completed validation for replacing nylon.



Headliners for EV3 Studycar

3Q 2025



Introduced as a partner for sustainable material technology in the 2025 Hyundai Motor Company Sustainability Report

## Expanding application in Packaging

F&B



Cosmetics & Household goods



Work with packaging partners that collaborate with multiple global brand owners, enabling systematic, stage-by-stage management of commercialization based on joint co-development

Expansion driven by higher processing stability and quality compared to MR PET

Completed quality validation of CR PET, meeting the advantages and required performance of conventional materials

1) Under the Single-Use Plastics Directive (SUPD), all PET bottles produced within the EU must contain at least 25% recycled plastic from 2025, and at least 30% from 2030

2) EU Council adopts ELV regulation mandating recycled plastic usage: 15% in 6 years, 20% in 8 years, and 25% in 10 years to reduce environmental impact and promote circularity in automotive materials.

# SK Multiutility – Combined Heat and Power Generation (CHP) Plant

## Securing competitiveness in the utilities business by broadening Distributed Energy demand points and ensuring stable operations

# Business Introduction

## ▪ **Business Overview**

- Convert to LNG-LPG, establishing eco-friendly district energy system
- Stable industrial power and steam supply within the area

- **CAPEX**: Approximately 673 Billion KRW<sup>1)</sup>

## ▪ **Expected Benefits**


- Eco-friendly energy transition reflecting carbon-neutral policies.
- Generating stable revenue by directly supplying electricity and steam to customers

- **Facility Production Capacity**

Steam : 240t/h . Electricity : 300MW (old facilities phased out)



### △ Rendering of the new LNG CHP plant



# 3 Appendix


---

**Financial Statements**

**Key Financial Information**

**Governance and Shareholders**

**Shareholder Returns**



# Financial Statements (Consolidated)

## Balance Sheet

(Unit: billion KRW)

Items	2024	2025
<b>Current assets</b>	<b>2,385</b>	<b>2,532</b>
- Current account	1,819	1,906
- Inventory	566	625
<b>Non-current assets</b>	<b>2,983</b>	<b>3,546</b>
- Investment in affiliated companies and joint ventures	10	10
- Tangible property	2,459	2,729
- Intangible property	163	228
- Other Non-current assets	351	579
<b>Total assets</b>	<b>5,368</b>	<b>6,078</b>
<b>Current liabilities</b>	974	1,119
<b>Non-current liabilities</b>	1,360	1,818
<b>Total liabilities</b>	<b>2,334</b>	<b>2,938</b>
<b>Equity attributable to the parent company</b>	2,202	2,259
- Capital stock	99	99
- Consolidated capital surplus	1,240	1,242
- Consolidated other components of equity	△22	△18
- Accumulated other comprehensive income	22	51
- Consolidated earned surplus	862	884
<b>Non-controlling interest</b>	832	881
<b>Total equity</b>	<b>3,034</b>	<b>3,140</b>
<b>Total liabilities and equity</b>	<b>5,368</b>	<b>6,078</b>

## Income Statement

(Unit: billion KRW)

Items	4Q24	1Q25	2Q25	3Q25	4Q25
<b>Revenue</b>	<b>514</b>	<b>537</b>	<b>597</b>	<b>610</b>	<b>622</b>
- Cost of Revenue	412	403	477	461	525
- Gross profit from Revenue	102	134	120	149	97
- Revenue and administrative expenses	131	109	121	133	136
<b>Operating profits</b>	<b>-29</b>	<b>24</b>	<b>△1</b>	<b>16</b>	<b>△39</b>
- Other non-operating income	33	3	10	15	34
- Other non-operating expense	13	2	4	7	5
- Financial income	35	25	21	26	27
- Financial expense	34	30	31	29	35
- Share of profits	△0.1	1	1	0.4	△0.2
<b>Earnings before interest and taxes</b>	<b>△9</b>	<b>20</b>	<b>△4</b>	<b>20</b>	<b>△19</b>
- Income tax expense	△19	△2	△12	△28	31
<b>Consolidated net income</b>	<b>10</b>	<b>21</b>	<b>8</b>	<b>48</b>	<b>△50</b>
- Equity attributable to the parent company	8	20	14	43	△32
- Non-controlling interest	2	1	△6	5	△18

# Financial Statements (Separate)

## Balance Sheet

Items	2024	2025
<b>Current assets</b>	<b>812</b>	<b>995</b>
- Current account	559	645
- Inventory	253	349
<b>Non-current assets</b>	<b>1,294</b>	<b>1,329</b>
- Investment in affiliated companies and joint ventures	444	500
- Tangible property	708	651
- Intangible property	31	33
- Other Non-current assets	110	145
<b>Total assets</b>	<b>2,106</b>	<b>2,323</b>
<b>Current liabilities</b>	<b>708</b>	<b>816</b>
<b>Non-current liabilities</b>	<b>236</b>	<b>278</b>
<b>Total liabilities</b>	<b>944</b>	<b>1,093</b>
Capital	99	99
Capital surplus	158	160
Other components of equity	△13	△9
Earned surplus	917	979
<b>Total equity</b>	<b>1,161</b>	<b>1,230</b>
<b>Total liabilities and equity</b>	<b>2,106</b>	<b>2,323</b>

## Income Statement

Items	4Q24	1Q25	2Q25	3Q25	4Q25
<b>Revenue</b>	<b>347</b>	<b>347</b>	<b>384</b>	<b>374</b>	<b>338</b>
- Cost of Revenue	254	255	297	270	265
- Gross profit from Revenue	92	92	87	102	73
- Revenue and administrative expenses	61	55	62	72	69
<b>Operating profits</b>	<b>32</b>	<b>37</b>	<b>25</b>	<b>30</b>	<b>4</b>
- Other non-operating income	2	2	8	14	2
- Other non-operating expense	10	1	4	7	4
- Financial income	22	13	12	5	19
- Financial expense	22	16	22	10	20
<b>Earnings before interest and taxes</b>	<b>24</b>	<b>34</b>	<b>20</b>	<b>31</b>	<b>1</b>
- Income tax expense	4	7	4	7	△1
<b>Net income</b>	<b>20</b>	<b>27</b>	<b>16</b>	<b>25</b>	<b>2</b>


# I Key Financial Information (Separate)




Division	2023					2024					2025				
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total
Cash and Cash Equivalents	326	222	215	245	<b>245</b>	250	407	341	177	<b>177</b>	301	324	322	458	<b>458</b>
Net Debt	387	412	393	360	<b>360</b>	423	414	397	403	<b>403</b>	426	446	424	344	<b>344</b>
CAPEX	81	24	23	31	<b>159</b>	21	22	16	15	<b>74</b>	10	11	11	19	<b>52</b>
Debt Ratio	82.9%	71.5%	69.9%	74.0%	<b>74.0%</b>	76.4%	90.3%	81.3%	68.4%	<b>68.4%</b>	80.4%	80.6%	78.0%	88.9%	<b>88.9%</b>
Current Ratio	128.9%	133.6%	125.7%	103.1%	<b>103.1%</b>	91.5%	112.0%	114.7%	120.5%	<b>120.5%</b>	139.5%	123.6%	128.7%	121.9%	<b>121.9%</b>
EBITDA	39	34	38	31	<b>141</b>	33	46	44	48	<b>171</b>	53	41	46	20	<b>160</b>
EBITDA (%)	12.6%	10.4%	11.8%	9.4%	<b>11.0%</b>	10.0%	13.2%	13.3%	14.2%	<b>12.6%</b>	15.3%	10.7%	12.4%	5.9%	<b>11.1%</b>
ROE	1.5%	0.4%	1.2%	0.6%	<b>3.7%</b>	0.8%	2.2%	1.3%	1.7%	<b>6.1%</b>	2.2%	1.3%	2.0%	0.2%	<b>5.6%</b>

# I Governance and Shareholders

## Governance




## Shareholder Composition



# Shareholder Returns

## Dividend

### Payout Ratio



1) The amount includes special dividends, with a dividend of 4,500 KRW per share based on the pre-bonus issue in 2021

2) Includes interim dividends 400KRW

3) Record Date of Shareholder Closure is March 31, 2026

## Others

**Jun 2017**

Retirement of Stock<sup>1)</sup>

**Oct 2021**

Announced dividend policy<sup>2)</sup>

**Nov 2021**

50% capital increase without consideration

**Mar 2022**

Announced Buy-back of Stock (50 Bn KRW)

**Oct 2022**

Retirement of Stock (50 Bn KRW)<sup>3)</sup>

1) Retired 1,939,120 common shares (7.9% of the total issued shares)

2) Total dividend amount determined at a payout ratio of approximately 30% (based on separate net income excluding non-recurring gains and losses)

3) Retired 389,489 common shares

# 4 Business Introduction

---


**Green Chemicals  
Life Science  
Global Network**



# Business Introduction Green Chemicals - Copolyester

## Business Introduction

- Functional PETG replaces PC, PMMA, PVC
- Production Process



- Key Products and Applicability



## Core Strategy

- Virgin : Stable profit through high-value goods/portfolio improvement
- Recycle : Establishing entry barriers through market preemption and property standardization

### Core Tasks and Strategy

#### Preempting CR Copolyester Market

- Expanding Recycle sales by cooperating with Global B/O
- Early customer commitments through MOUs, etc.

#### High-Value Portfolio Expansion

- Targeting High-Value Markets Based on Quality Competency
  - Expanding sales in high-value end-markets (cosmetics/HHG/HA)
  - Leading standardization by securing cosmetics B/O
  - Expanding sales through new applications, replacing other materials
- Expanding Strategic Products/Markets by Facility Optimization
  - Shortening the expansion period of heat-resistant copolyester through investment in upgrading facility
  - Accelerating M/S expansion through property enhancement and application expansion

1) R-BHET : Recycled bis-(2-hydroxyethyl) terephthalate, Partial or Full Replacement of Fossil-Based Feedstocks for PTA and MEG 2) CHDM : Cyclohexanedimethanol 3) Use of Biomass-Derived Ingredients (total content ≤15%; biomass content determined via radiocarbon analysis in accordance with ASTM D6866)

# Business Introduction Green Chemicals - Recycle


## Business Introduction

### Production Process



### Mechanical Recycling vs. Chemical Recycling Comparison

Pursuing a Closed-Loop Model via Glycolysis-Based Chemical Recycling



## Core Strategy

- Acquired competency as the 1<sup>st</sup> to commercialize CR-PET in 2023
- Leading the CR-PET market through quality and cost competency

### Core Tasks and Strategy

#### Vertical Integration of Raw Material Supply: Feedstock Innovation

- Internalizing key recycled raw materials (R-BHET) SK Shantou
- Expanding W-PET value chain through extended partnerships

#### Stabilization of SK Shantou and Advancing of HTR Technology

- Price and quality competitiveness of recycled products and expanding R-BHET production capacity
- Purification process improvement → washing process Normalization → HTR Conversion

#### Securing Cost Competitiveness at the Level of MR-PET

- Reduction in production costs: Alleviating customer price resistance and promoting market development


#### Strategic Expansion of CR-PET Sales

- Securing opportunities in the high-value CR-PET market and mass market based on cost competitiveness

# Business Introduction Green Chemicals - Circular

## Business Introduction

- Aim to enable Circular Economy Solution for Recycling Waste PET Generated During Customers' Production Processes
- Chemical Recycling for Enhanced Circularity



## Core Strategy

- Recycling market is expected to form across various industries due to recycling regulations



EEE  
WEEE<sup>1)</sup>

- Obligated to recover and recycle 55-80% of production volume



Automotive  
ELV<sup>2)</sup>

- Need to establish a closed loop for consumables generated during the process



Fashion  
ESPR<sup>3)</sup>

- Obligation to use easily disassembled designs and recyclable/reusable materials
- Need to establish a closed loop for waste obtained from end-of-life vehicles

- Compliance Obligations for Apparel Producers: Ecodesign and Energy Labelling, Considering Energy/Resource Efficiency and Recycled Content
- Textiles and apparel are included among the five priority product groups subject to ESPR requirements

... and many other industry needs

1) Waste of Electrical & Electronic Equipment: EU directive on the manufacture/use/disposal of electrical/electronic equipment


2) End of Life Vehicles Regulation: EU regulation on the recycling/reuse of end-of-life vehicles (legislative process underway)

3) Eco-design for Sustainable Products Regulation: EU regulation for eco-design of sustainable products

# Business Introduction Green Chemicals – Other Business

## BIO Materials

- Bio-Materials<sup>4)</sup>, replacing fossil-based fuels, is Performance Bio-Polyol that Replaces Polyurethane Uses which is Difficult to Recycle
- Targeting eco-friendly needs by increasing applicability and cost competitiveness



High elastic recovery,  
wear resistance,  
high flexibility

Lower CO<sub>2</sub> Emissions  
Compared to Fossil-  
Derived BDO

Commercialized in  
February 2022 CAPA:  
5,000 Tons/yr

### ▪ Key Markets and Commercialization Examples



Spandex



Synthetic  
Leather



Black Yak shoe insoles  
(Elastomer/Foam)



SRIXON Golf ball  
(Urethane Cover)

\* ECOTRION achieved USDA and TUV certifications verifying Bio-Based Content

1) PDO : Propanediol 2) PO3G : Poly Oxytrimethylene Glycol 3) TPEE: thermoplastic polyester elastomer 4) Bio-materials refers to products made from corn-based biomass


5) Approximately 40% Reduction in Greenhouse Gas Emissions with Bio-Based PDO Compared to Fossil-Derived BDO (Based on Supplier LCA)

## Functional Materials

- Polyester-based adhesives and coatings (BON) and TPEE(PEL)
- Eco-friendly needs in various areas: Increased demand for chemical resistance and conversion to recycled products
- Product Introduction and Applicability

**SKY BON**

- Polyester-based adhesives and coatings
- Can Coating, Pre-coated metal, Hotmelt, Industrial adhesives, etc.



**SKY PEL**

- TPEE<sup>3)</sup>
- Cable Jacket, Industrial tubes, Duct Mesh Chair Monofilament, etc.



# Business Introduction Life Science - Pharma

## Business Introduction

- Competitive product portfolio in botanical and synthetic drug market
- Possesses top-level marketing and partnership capabilities domestically

### ▪ Main Products

#### Ginexin-F



ginkgo leaf blood circulation and cognitive function enhancer

#### Joins



Natural arthritis treatment

#### Trast



Patch-type arthritis treatment

#### Mvix S



World's first film-type erectile dysfunction treatment

#### Rivastigmine Patch



Patch-type dementia treatment

## Core Strategy

Continuous business expansion through securing growth drivers based on competency

### Mid-term Key Tasks

Strengthening marketing alliance competitiveness

Natural pharmaceutical Product value-up

Expanding Global C(D)MO

Securing R&D growth drivers

### Implementation Strategy

Strengthening strategic partnership and operation optimization

Diversifying raw material sourcing and expanding sales

Exploring new Countries for New CMO opportunities

Expanding to new pipelines and accelerating open Innovation



Exploring New Biz Model

# Global Network

● HQ(1) ● Domestic Plants(3) ● Overseas Offices (2) ● Overseas Plants (3) ● Overseas Corporations(4)

Dessau-Rosslau

Frankfurt

Yantai  
Shanghai  
Shantou  
Guangzhou

Kuala Lumpur

Tokyo

Cheongju(S HOUSE)  
Andong(L HOUSE)

Ulsan(Ulsan Plant)

Korea

HQ(ECO Lab)

Irvine

## SK Shantou

**Certification**

2019 r-BHET , CR-PET Plant takeover (Shuye)  
Mar 2023 Acquisition of Tangible Assets (Shuye)

**Construction**

r-BHET , CR-PET etc.

**Production Capacity**

r-BHET : 70K tons / CR-PET 50K tons Annually



## Ulsan Plant



**Certification** ISO 14001(Environment) / ISO 45001 (Safety and Health) / ISO 9001(Quality)

**Construction** Sept 1989 PTA / DMT Plant completion

Jan 2001 CHDM / PETG Plant completion

Feb 2022 PO3G Plant completion

**Products** Copolyester resin, DMT, PO3G etc.

**Production Capacity** 470K tons Annually <sup>1)2)</sup>

## Cheongju Plant (S HOUSE)



**Certification** K GMP/ EU GMP(Solid tablets, patches)

**Construction** July 2009 Cheongju plant acquisition

July 2012 Production building completion

Mar 2014 Patch building reconstruction

**Products** Solid tablets and patches

**Production Capacity** 760 mil. solid tablets, 66 mil. patch pouches annually

## Andong Plant (L HOUSE)



**Certification** MFDS & EU GMP Certification

**Construction** Dec 2012 Construction Completed

**Products** Flu vaccine, varicella/herpes zoster vaccine, COVID vaccine (CMO/CDMO)

**Production Capacity** Approximately 500 mil. doses annually based on finished products

1) Total capacity including PETG, DMT etc.